CY2570B1 - Compounds for immunotherapy and diagnosis of tuberculosis - Google Patents

Compounds for immunotherapy and diagnosis of tuberculosis

Info

Publication number
CY2570B1
CY2570B1 CY0600033A CY0600033A CY2570B1 CY 2570 B1 CY2570 B1 CY 2570B1 CY 0600033 A CY0600033 A CY 0600033A CY 0600033 A CY0600033 A CY 0600033A CY 2570 B1 CY2570 B1 CY 2570B1
Authority
CY
Cyprus
Prior art keywords
tuberculosis
compounds
diagnosis
immunotherapy
polypeptides
Prior art date
Application number
CY0600033A
Other languages
English (en)
Inventor
Yasir A W Skeiky
Thomas S Vedvick
Steven G Reed
Antonio Campos-Neto
Daniel R Twardzik
Davin C Dillon
Raymond L Houghton
Original Assignee
Corixa Corp Csc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2570(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corixa Corp Csc filed Critical Corixa Corp Csc
Publication of CY2570B1 publication Critical patent/CY2570B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY0600033A 1995-09-01 2006-12-19 Compounds for immunotherapy and diagnosis of tuberculosis CY2570B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52343695A 1995-09-01 1995-09-01
US53363495A 1995-09-22 1995-09-22
US62087496A 1996-03-22 1996-03-22
US65968396A 1996-06-05 1996-06-05
US68057496A 1996-07-12 1996-07-12

Publications (1)

Publication Number Publication Date
CY2570B1 true CY2570B1 (en) 2008-07-02

Family

ID=27541835

Family Applications (2)

Application Number Title Priority Date Filing Date
CY0600033A CY2570B1 (en) 1995-09-01 2006-12-19 Compounds for immunotherapy and diagnosis of tuberculosis
CY0900006A CY2612B2 (en) 1995-09-01 2009-06-05 Compounds for immunotherapy and diagnosis of tuberculosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY0900006A CY2612B2 (en) 1995-09-01 2009-06-05 Compounds for immunotherapy and diagnosis of tuberculosis

Country Status (24)

Country Link
EP (5) EP1398379B1 (ja)
JP (5) JP4382160B2 (ja)
KR (1) KR100433750B1 (ja)
CN (1) CN1117149C (ja)
AT (5) ATE252640T1 (ja)
AU (1) AU727602B2 (ja)
BR (2) BR9610262B1 (ja)
CA (3) CA2230885C (ja)
CY (2) CY2570B1 (ja)
CZ (3) CZ300953B6 (ja)
DE (4) DE69637879D1 (ja)
DK (4) DK1347055T3 (ja)
ES (4) ES2262595T3 (ja)
HK (1) HK1059282A1 (ja)
HU (2) HU227778B1 (ja)
IL (1) IL123506A (ja)
MX (1) MX9801638A (ja)
NO (4) NO324372B1 (ja)
NZ (1) NZ319377A (ja)
PL (1) PL186774B1 (ja)
PT (4) PT851927E (ja)
SI (1) SI0851927T1 (ja)
TR (5) TR200806258T2 (ja)
WO (1) WO1997009428A2 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
CZ126699A3 (cs) * 1996-10-11 1999-09-15 Corixa Corporation Polypeptid obsahující antigenní část rozpustného antigenu M. tuberculosis nebo variantu uvedeného antigenu, molekula DNA kódující tento polypeptid, expresivní vektor, hostitelská buňka, způsoby diagnostiky infekce M. tuberculosis a diagnostické kity
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
ATE370236T1 (de) * 1997-04-02 2007-09-15 Statens Seruminstitut Nukleinsäure- und polypeptidfragmente von m. tuberculosis
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
CA2296419A1 (en) * 1997-07-16 1999-01-28 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
AU750173B2 (en) * 1997-11-10 2002-07-11 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
EP1484405A1 (en) * 1997-11-10 2004-12-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
CN1629185B (zh) * 1998-04-07 2011-11-02 科里克萨公司 结核杆菌抗原融合蛋白及其应用
GB9808720D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
AU6480999A (en) * 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
CA2372583C (en) 1999-05-04 2012-07-10 The Public Health Research Institute Of The City Of New York, Inc. Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
US7009042B1 (en) * 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
SI1542732T1 (sl) 2000-06-20 2010-01-29 Corixa Corp Csc The United Sta Fuzijski proteini Mycobacterium tuberculosis
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
FI119445B (fi) * 2004-10-29 2008-11-14 Waertsilae Finland Oy Polttomoottorin polttoaineen syöttöjärjestelmän paineen värähtelyn vaimennin
CA2586620C (en) 2004-11-16 2014-06-03 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
DK1877426T3 (da) 2005-04-29 2012-05-14 Glaxosmithkline Biolog Sa Fremgangsmåde til forebyggelse eller behandling af M Tuberculosis-infektion.
FR2952058B1 (fr) 2009-10-29 2013-10-04 Centre Nat Rech Scient Procede de ligation native de polypeptides
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
US9352030B2 (en) 2010-12-14 2016-05-31 Glaxosmithkline Biologicals, S.A. Mycobacterium antigenic composition
FR2971509B1 (fr) * 2011-02-16 2013-02-22 Centre Nat Rech Scient Procede de preparation de peptides par assemblage de multiples fragments peptidiques
CN103290030A (zh) * 2012-02-23 2013-09-11 上海交通大学 一种结核分枝杆菌标志物HtdY的重组蛋白及其制备方法和临床应用
DK2844282T3 (da) * 2012-05-04 2019-07-15 Pfizer Prostata-associerede antigener og vaccine-baserede immunterapiregimener
US20170121377A1 (en) * 2014-04-04 2017-05-04 Vestaron Corporation Artificially activated toxic peptides
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
FR3048286B1 (fr) * 2016-02-26 2021-01-22 Omunis Peptides immunogenes et leur utilisation
CN107304231B (zh) * 2016-04-18 2021-01-01 华中农业大学 一种结核分枝杆菌融合蛋白及应用
GB201614485D0 (en) * 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2244539A1 (en) * 1973-07-13 1975-04-18 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
FR2265402A1 (en) * 1974-03-29 1975-10-24 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
US4876089A (en) * 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
FR2677365B1 (fr) * 1991-06-07 1995-08-04 Pasteur Institut Proteines de mycobacterium et applications.
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
DK79793D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
DK79893D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine

Also Published As

Publication number Publication date
HUP9900902A2 (hu) 1999-07-28
NO980883L (no) 1998-04-27
TR199800411T1 (xx) 1998-05-21
JP2006149406A (ja) 2006-06-15
ATE426025T1 (de) 2009-04-15
JP4324597B2 (ja) 2009-09-02
JP2006187292A (ja) 2006-07-20
ES2262595T3 (es) 2006-12-01
CN1200147A (zh) 1998-11-25
EP1347055B1 (en) 2009-03-18
BR9610262B1 (pt) 2013-11-26
EP1398379A3 (en) 2004-07-14
NO20070618L (no) 1998-04-27
TR200403064T2 (tr) 2005-08-22
EP0851927A2 (en) 1998-07-08
ATE252640T1 (de) 2003-11-15
ES2271449T3 (es) 2007-04-16
CZ297406B6 (cs) 2006-12-13
KR100433750B1 (ko) 2004-09-01
JP2001517069A (ja) 2001-10-02
CN1117149C (zh) 2003-08-06
NO324372B1 (no) 2007-10-01
EP0851927B1 (en) 2003-10-22
NO336288B1 (no) 2015-07-13
HUP9900902A3 (en) 2001-03-28
EP1398379A2 (en) 2004-03-17
PT1398379E (pt) 2007-01-31
DE69636046D1 (de) 2006-05-24
JP2009159982A (ja) 2009-07-23
WO1997009428A2 (en) 1997-03-13
EP1347055A2 (en) 2003-09-24
PT851927E (pt) 2004-03-31
HU225979B1 (en) 2008-02-28
DE69636487D1 (de) 2006-10-05
DE69637879D1 (de) 2009-04-30
CA2230885C (en) 2010-02-02
EP1347055A3 (en) 2003-11-26
NO980883D0 (no) 1998-02-27
AU727602B2 (en) 2000-12-14
JP4382160B2 (ja) 2009-12-09
EP1203817B9 (en) 2006-08-16
PT1347055E (pt) 2009-06-19
PL186774B1 (pl) 2004-02-27
AU7158696A (en) 1997-03-27
CZ300953B6 (cs) 2009-09-23
JP2007228972A (ja) 2007-09-13
MX9801638A (es) 1998-05-31
CZ62898A3 (cs) 1999-10-13
JP4324618B2 (ja) 2009-09-02
DK1203817T3 (da) 2006-08-14
SI0851927T1 (en) 2004-02-29
DE69636487T2 (de) 2007-05-03
IL123506A0 (en) 1998-10-30
NO20070621L (no) 1998-04-27
CA2684425A1 (en) 1997-03-13
CA2653566C (en) 2013-06-25
DK0851927T3 (da) 2004-01-26
IL123506A (en) 2004-12-15
TR200806258T2 (tr) 2008-10-21
EP1203817A3 (en) 2003-01-29
PT1203817E (pt) 2006-08-31
EP1203817A2 (en) 2002-05-08
ES2210392T3 (es) 2004-07-01
ATE513915T1 (de) 2011-07-15
BR9610262A (pt) 1999-07-06
CA2230885A1 (en) 1997-03-13
WO1997009428A3 (en) 1997-07-17
DK1398379T3 (da) 2007-01-08
EP1203817B1 (en) 2006-04-12
DE69630457D1 (de) 2003-11-27
CA2653566A1 (en) 1997-03-13
DK1347055T3 (da) 2009-06-29
EP1712628A2 (en) 2006-10-18
TR200806259T2 (tr) 2008-10-21
HU227778B1 (en) 2012-02-28
PL325373A1 (en) 1998-07-20
CZ300688B6 (cs) 2009-07-15
EP1398379B1 (en) 2006-08-23
EP1712628B1 (en) 2011-06-22
NO20070619L (no) 1998-04-27
ATE337399T1 (de) 2006-09-15
BR9612997B1 (pt) 2012-01-10
ATE323165T1 (de) 2006-04-15
DE69630457T2 (de) 2004-11-25
NZ319377A (en) 2000-01-28
KR19990044347A (ko) 1999-06-25
DE69636046T2 (de) 2006-11-23
TR200901109T1 (tr) 2012-02-21
EP1712628A3 (en) 2007-05-23
JP4324596B2 (ja) 2009-09-02
HK1059282A1 (en) 2004-06-25
ES2324529T3 (es) 2009-08-10
CY2612B2 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
CY2612B2 (en) Compounds for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO2002024739A3 (en) Spas-1 cancer antigen
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους